title: Phase I study of suramin administered by intermittent infusion without adaptive control to cancer patients: update of two expanded dose levels near the maximally tolerated dose.
authors.forename: K
authors.initials: K
authors.lastname: Kobayashi
authors.forename: E E
authors.initials: EE
authors.lastname: Vokes
authors.forename: N J
authors.initials: NJ
authors.lastname: Vogelzang
authors.forename: L
authors.initials: L
authors.lastname: Janisch
authors.forename: B
authors.initials: B
authors.lastname: Soliven
authors.forename: M J
authors.initials: MJ
authors.lastname: Ratain
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D017321:Clinical Trials, Phase I as Topic; D006801:Humans; D007262:Infusions, Intravenous; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D013498:Suramin / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D000970:Antineoplastic Agents; D013498:Suramin